当飞利肝宁胶囊对乙肝肝硬化代偿期患者肝功能、肝纤维化指标的影响  

Effect of Dangfei Liganning Capsule on Liver Function and Hepatic Fibrosis Indexes in Patients with Hepatitis B Cirrhosis in Compensatory Stage

作　　者：冀丽娟 王立新[2] 陈艳 金伟[1] JI Lijuan;WANG Lixin;CHEN Yan;JIN Wei(Department of Gastroenterology,Yidu Central Hospital,Weifang 262550,Shandong,China;Endoscopy Room,Yidu Central Hospital,Weifang 262550,Shandong,China)

机构地区：[1]潍坊市益都中心医院消化内科,山东潍坊262550 [2]潍坊市益都中心医院内镜室,山东潍坊262550

出　　处：《世界复合医学（中英文）》2024年第8期73-76,共4页World Journal of Complex Medicine

摘　　要：目的探究当飞利肝宁胶囊对乙肝肝硬化代偿期患者肝功能、肝纤维化指标的影响。方法选取2021年1月—2022年12月潍坊市益都中心医院收治的86例乙肝肝硬化代偿期患者为研究对象,按治疗方法的不同分为观察组和对照组,每组43例。对照组接受常规西药治疗,观察组在对照组基础上给予当飞利肝宁胶囊治疗。比较两组患者肝功能、肝纤维化指标水平。结果治疗前,两组谷草转氨酶、谷丙转氨酶、总胆红素水平对比,差异无统计学意义(P均>0.05);治疗后,观察组谷草转氨酶、谷丙转氨酶、总胆红素水平均低于对照组,差异有统计学意义(P均<0.05)。治疗前,两组层粘连蛋白、Ⅳ型胶原、透明质酸、Ⅲ型前胶原N端肽水平对比,差异无统计学意义(P均>0.05);治疗后,观察组层粘连蛋白水平为(92.16±5.32)μg/L、Ⅳ型胶原水平为(112.17±11.43)μg/L、透明质酸水平为(93.42±13.22)ng/mL、Ⅲ型前胶原N端肽水平为(15.54±0.86)μg/L,均低于对照组的(93.33±5.42)μg/L、(114.69±11.57)μg/L、(96.49±13.36)ng/mL、(15.72±0.88)μg/L,差异有统计学意义(t=3.268、3.287、3.465、3.103,P均<0.05)。结论给予乙肝肝硬化代偿期患者当飞利肝宁胶囊可以改善其肝功能和肝纤维化情况。Objective To explore the effect of Dangfei Liganning Capsule on liver function and hepatic fi⁃brosis indexes in patients with hepatitis B cirrhosis in compensatory stage.Methods A total of 86 patients with hepatitis B cirrhosis in compensatory stage admitted to Weifang Yidu Central Hospital from January 2021 to De⁃cember 2022 were selected as the research objects.According to different treatment methods,they were divided into observation group and control group,with 43 cases in each group.The control group was treated with con⁃ventional Western medicine,and the observation group was treated with Dangfei Liganning Capsule on the basis of the control group.The levels of liver function and liver fibrosis indexes were compared between the two groups.Results Before treatment,there were no statistically significant differences in the levels of aspartate ami⁃notransferase,alanine aminotransferase and total bilirubin between the two groups(all P>0.05).After treatment,the levels of aspartate aminotransferase,alanine aminotransferase and total bilirubin in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Before treatment,there were no significant differences in the levels of laminin,collagen typeⅣ,hyaluronic acid and N-terminal peptide of typeⅢprocollagen between the two groups(all P>0.05).After treatment,the levels of laminin,collage typeⅣ,hyaluronic acid and N-terminal peptide of typeⅢprocollagen in the observation group were(92.16±5.32)μg/L,(112.17±11.43)μg/L,(93.42±13.22)ng/mL and(15.54±0.86)μg/L,respec⁃tively,which were lower than(93.33±5.42)μg/L,(114.69±11.57)μg/L,(96.49±13.36)ng/mL and(15.72±0.88)μg/L in the control group,and the differences were statistically significant(t=3.268,3.287,3.465,3.103,all P<0.05).Conclusion Dangfei Liganning Capsule can improve liver function and hepatic fibrosis indexes in pa⁃tients with hepatitis B cirrhosis in compensatory stage.

关 键 词：当飞利肝宁胶囊 肝纤维化指标 乙肝肝硬化代偿期 谷丙转氨酶 谷草转氨酶 

分 类 号：R575[医药卫生—消化系统]